Joel Neal, MD, PhD

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Sanofi/Regeneron
    Topic:
    advisory/consulting
    Date added:
    06/13/2023
    Date updated:
    03/14/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    D2G Oncology
    Topic:
    advisory/consulting
    Date added:
    06/13/2023
    Date updated:
    03/14/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Surface Oncology
    Topic:
    advisory/consulting
    Date added:
    06/13/2023
    Date updated:
    03/14/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Turning Point Therapeutics
    Topic:
    advisory/consulting
    Date added:
    06/13/2023
    Date updated:
    03/14/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Mirati Therapeutics
    Topic:
    advisory/consulting
    Date added:
    06/13/2023
    Date updated:
    03/14/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Gilead
    Topic:
    advisory/consulting, research funding
    Date added:
    06/13/2023
    Date updated:
    03/14/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    AbbVie
    Topic:
    advisory/consulting, research funding
    Date added:
    06/13/2023
    Date updated:
    03/14/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Summit Therapeutics
    Topic:
    advisory/consulting
    Date added:
    06/13/2023
    Date updated:
    03/14/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Novartis
    Topic:
    advisory/consulting, research funding
    Date added:
    06/13/2023
    Date updated:
    03/14/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Novocure
    Topic:
    advisory/consulting, research funding
    Date added:
    06/13/2023
    Date updated:
    03/14/2024

Pages

Return to 2023 Precision Oncology Summit: Personalizing Treatment to Improve Patient Outcomes